Reaction

Gastrointestinal Obstruction reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,358 reports · 44 co-occurring drugs

As of the last recalculation, Gastrointestinal Obstruction appears in 2,358 FAERS reports alongside 44 co-occurring drug terms. The strongest observed disproportionality signal is TEDUGLUTIDE (PRR 18.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Teduglutide	28	18.6	18.6
Polatuzumab Vedotin	20	18.2	18.3
Adalimumab	780	14.0	14.1
Risankizumab-Rzaa	99	11.1	11.1
Infliximab-Dyyb	33	10.1	10.1
Loperamide Hydrochloride And Dimethicone	34	9.5	9.5
Psyllium Husk	9	8.1	8.1
Cholestyramine	11	8.1	8.1
Vedolizumab	76	8.0	8.0
Diphenoxylate Hydrochloride And Atropine Sulfate	12	7.8	7.8
Octreotide Acetate	26	7.6	7.6
Mesna Injection	7	7.5	7.5
Bendamustine Hcl	13	7.4	7.4
Loperamide Hydrochloride	37	7.4	7.4
Mesna	7	7.4	7.4
Lumacaftor And Ivacaftor	7	7.2	7.2
Pancrelipase	31	7.2	7.2
Panitumumab	11	6.2	6.2
Dornase Alfa	13	5.9	5.9
Leucovorin Calcium	12	5.6	5.6
Oxaliplatin	46	5.6	5.6
Rifampicin	6	5.2	5.2
Amikacin	10	5.2	5.2
Gemcitabine	22	5.0	5.0
Elexacaftor, Tezacaftor, And Ivacaftor	7	5.0	5.0
Pyrazinamide	5	4.7	4.7
Cisplatin	40	4.6	4.6
Erlotinib	5	4.6	4.6
Gemcitabine Hydrochloride	27	4.5	4.5
Tobramycin	12	4.4	4.4
Obinutuzumab	8	4.3	4.3
Erlotinib Hydrochloride	6	4.2	4.2
Fluorouracil Cream, 0.5%	36	4.2	4.2
Fluorouracil	36	4.2	4.2
Trifluridine And Tipiracil	5	4.1	4.1
Capecitabine	41	4.0	4.0
Niraparib	10	4.0	4.0
Upadacitinib	35	3.8	3.8
Lenvatinib	13	3.5	3.5
Ustekinumab	40	3.5	3.5
Clozapine	48	3.4	3.4
Encorafenib	3	2.7	2.7
Erenumab-Aooe	12	1.9	1.9
Droxidopa	3	1.2	1.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.